Business Context and Reporting Period
This Form 8-K reports on events occurring at the Annual Meeting of Stockholders for Niagen Bioscience, Inc. held on June 24, 2025. The filing details the results of shareholder votes and the approval of specific corporate governance and equity plans.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding corporate governance and equity plan approvals. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Shareholder Actions
The following material actions were approved by stockholders at the Annual Meeting:
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares available for issuance by 4,750,000 shares.
- Employee Stock Purchase Plan (ESPP): Stockholders approved a new ESPP allowing officers and employees to purchase shares via payroll deductions. The plan offers shares at a discount of 85% of the lesser of the closing price on the purchase date or the offering date. The total shares available for issuance are capped at 650,000.
- Director Elections: Eight directors were elected to serve until the 2026 Annual Meeting. All nominees received significant "For" votes, though Steven Rubin received a notable number of withheld votes (12,428,060).
- Accounting Firm Ratification: Crowe LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: The advisory vote on executive compensation was approved.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document focuses strictly on the procedural outcomes of the Annual Meeting. The approval of the ESPP and the increase in the equity incentive pool may result in future dilution to existing shareholders, though specific dilution impacts are not quantified in this text.
Key Facts for Investor Verification
- Verify the total authorized share count to assess the dilution impact of the newly approved 4.75 million shares for the 2017 Plan and 650,000 shares for the ESPP.
- Review the definitive proxy statement (Schedule 14A filed April 29, 2025) for detailed terms of the equity plans referenced in this filing.
- Confirm the voting results for Director Steven Rubin, who received approximately 22% of votes withheld, compared to less than 1% withheld for other directors.
- Check subsequent filings for the actual issuance of shares under the new ESPP and the amended 2017 Plan.